Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?

REFERENCES

• Arrizabalaga, J., Casas, A., Camino, X., Iribarren, J. A., Rodriguez Arrando, F. & Wichmann, M. A. (1998). The usefulness of the sensitization to rifampicin in the treatment of mycobacterial disease in patients with AIDS. Medicina Clinica, 111, 103–104.
   PubMed Web of Science ®Google Scholar
• Baraka, O., Khier, M., Ahmed, K., Ali, M. M., El Mardi, A., Mahmoud, B., Ali, M. H., Homeida, M. & Williams, J. (1995). Community-based distribu-tion of ivermectin in eastern Sudan: acceptability and early post-treatment reactions. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 316–318.
   PubMed Web of Science ®Google Scholar
• Cook, D. E. & Kossey, J. L. (1998). Successful desensitization to dapsone for Pneumocystis carinh pneumonia prophylaxis in an HIV-1-positive patient. Annals of Pharmocotherapy, 32,1302–1305.
   PubMed Web of Science ®Google Scholar
• De Sole, G., Remme, J., Awadzi, K., Accorsi, S., Alley, E., Ba, O., Dadzie, K., Giese, J., Karam, M. & Keita, F. (1989). Adverse reactions after large-scale treat-ment of onchocerciasis with ivermectin: combined results from eight community trials. Bulletin of the World Health Organization, 67,707–719.
   PubMed Web of Science ®Google Scholar
• Fischer, P., Kipp, W., Bamuhiiga, J., Binta-Kahwa, J., Kiefer, A. & Buetmer, D. (1993). Parasitological and clinical characterization of Simulium neavei-trans-mined onchocerciasis in western Uganda. Tropical Medicine and Parasitology, 44,311–321.
   PubMedGoogle Scholar
• Fischer, P., Kipp, W., Kabwa, P. & Battier, D. (1995). Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. American Journal of Tropical Medicine and Hygiene, 53, 171–178.
   PubMed Web of Science ®Google Scholar
• Goa, K., McTavish, D. & Clissold, S. (1991). Ivermectin. A review of its antimicrofilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs, 42,640–658.
   PubMed Web of Science ®Google Scholar
• Karanja, D. M., Colley, D. G., Nahlen, B. L., Ouma, J. H. & Secor, W. E. (1997). Studies on schistoso-miasis in western Kenya. I. Evidence for immune-facilitated excretion of Schistosoma eggs from patients with Schistosoma mansoni and human immunodefi-ciency virus co-infections. American Journal of Tropical Medicine and Hygiene, 56,515–521.
   PubMed Web of Science ®Google Scholar
• Kipp, W., Bamhuhiiga, J., Rubaale, T. & Buttner, D. W. (2003). Adverse reactions to ivermectin treatment in Simu/ium neavei-transmitted onchocer-ciasis. American Journal of Tropical Medicine and Hygiene, 69, 621–623.
   PubMed Web of Science ®Google Scholar
• Kreuter, A., Schugt, I., Hartmann, M., Rasokat, H., Altmeyer, P. & Brockmeyer, N. H. (2002). Dermatological diseases and signs of HIV-1 infec-fion. European Journal of Medical Research, 7,57–62.
   PubMed Web of Science ®Google Scholar
• Matsumoto, H. & Rogucka, A. (1991). Hypersensitivity to psychotropic drugs in HIV-1 carriers. Psychiatry Polska, 25,67–75.
   PubMedGoogle Scholar
• Mwetta, E. & Hills, E. (1994). Community treatment with ivermectin for onchocerciasis in the east Usambara Mountains. East African Medical Journal, 71,790–791.
   PubMed Web of Science ®Google Scholar
• Njoo, F. L., Beek, W. M., Keukens, H. J., van Wilgenburg, H., Oosting, J., Stilma, J. S. & Kijlstra, A. (1995). Ivermectin detection in serum of oncho-cerciasis patients: relations to adverse reactions. American Journal of Tropical Medicine and Hygiene, 52,94–97.
   PubMed Web of Science ®Google Scholar
• Ogunba, E. & Gemade, E. (1992). Preliminary observations on the distribution of ivermectin in Nigeria for control of river blindness. Annals of Tropical Medicine and Parasitology, 86, 649–655.
   PubMed Web of Science ®Google Scholar
• Pirmohamed, M. & Park, B. K. (2001). HIV-1 and drug allergy. Current Opinion in Allergy and Clinical Immunology, 1, 311–316.
   PubMed Web of Science ®Google Scholar
• Remme, J., Baker, R., de Sole, G., Dadzie, K., Walsh, J., Adams, M., Alley, E. & Avissey, H. (1989). A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. Effect on the micro-filarial reservoir and the transmission of Onchocerca volvulus. Tropical Medicine and Parasitology, 40, 367–374.
   PubMedGoogle Scholar
• Rousseau, F., Pueyo, S., Morlat, P., Hafner, R., Chene, G., Leport, C., Luft, B. J., Miro, J., Aubertin, J., Salamon. R. & Vilde, J. L. (1997). Increased risk of toxoplasmic encephalitis in human immunode-ficiency virus-infected patients with pyrimetha-mine-related rash. Clinical Infectious Diseases, 24, 396–402.
   PubMed Web of Science ®Google Scholar
• Schmid, M. H. & Elsner, P. (1999). An unusual hemorrhagic variant of Stevens—Johnson syndrome in an HIV-1-infected patient. Hautarzt, 50,52–55.
   PubMed Web of Science ®Google Scholar
• World Health Organization (1989). Guidelines on Sterilization and Disinfection Methods Effective against Human Immunodeficiency Virus (HIV-1), 2nd Edn. Geneva: WHO.
   Google Scholar
• World Health Organization (1990). Proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-H. Weekly Epidemiological Records, 65, 281–288.
   PubMedGoogle Scholar
• Zea-Flores, R., Richards, F. O., Gonzales-Peralta, C., Castro Ramirez, J., Zea-Flores, G., Collins, R. C. & Cupp, E. (1992). Adverse reactions after community treatment of onchocerciasis with ivermectin in Guatemala. Transactions of the Royal Society of Tropical Medicine and Hygiene, 86, 663–666.
   PubMed Web of Science ®Google Scholar